Alcon has received all the required regulatory clearances relating to its tender offer for WaveLight AG.
Alcon has received all the required regulatory clearances relating to its tender offer for WaveLight AG.
Upon settlement of all tendered shares, Alcon will own 77.4% of the outstanding WaveLight shares and shareholders who tendered their shares under the offer will automatically receive payment.
COPHy 2023: Restorative therapies and the path to them
March 24th 2023In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.
APAO 2023: Keralink Trial and efficacy safety of corneal cross-linking for children with Keratoconus
February 25th 2023The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.
2 Clarke Drive
Cranbury, NJ 08512